FUSION PHARMACEUTICALS INC's ticker is FUSN and the CUSIP is 36118A100. A total of 33 filers reported holding FUSION PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $639,694 | -44.3% | 246,036 | 0.0% | 0.20% | -32.2% |
| Q2 2023 | $1,148,988 | +23.9% | 246,036 | 0.0% | 0.29% | -36.4% |
| Q1 2023 | $927,556 | +13.1% | 246,036 | -5.5% | 0.46% | +51.5% |
| Q4 2022 | $820,411 | +4.6% | 260,448 | 0.0% | 0.30% | +21.7% |
| Q3 2022 | $784,000 | +20.8% | 260,448 | 0.0% | 0.25% | +2.0% |
| Q2 2022 | $649,000 | -67.8% | 260,448 | +0.3% | 0.24% | -63.5% |
| Q1 2022 | $2,018,000 | +86.3% | 259,763 | 0.0% | 0.67% | +104.9% |
| Q4 2021 | $1,083,000 | -47.4% | 259,763 | 0.0% | 0.33% | -50.3% |
| Q3 2021 | $2,057,000 | -4.3% | 259,763 | -2.4% | 0.66% | +22.8% |
| Q2 2021 | $2,150,000 | -19.6% | 266,107 | +6.7% | 0.53% | -1.7% |
| Q1 2021 | $2,674,000 | +31.8% | 249,419 | +44.4% | 0.54% | +30.8% |
| Q4 2020 | $2,029,000 | +3801.9% | 172,693 | +5656.4% | 0.42% | +2666.7% |
| Q2 2020 | $52,000 | – | 3,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,670,516 | $9,543,342 | 3.52% |
| ADAMS STREET PARTNERS LLC | 2,947,809 | $7,664,303 | 2.68% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,560,982 | $4,058,553 | 1.62% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,354,258 | $3,521,071 | 0.64% |
| Avidity Partners Management LP | 5,781,850 | $15,032,810 | 0.60% |
| Eagle Health Investments LP | 579,769 | $1,507,399 | 0.33% |
| Perceptive Advisors | 2,751,395 | $7,153,627 | 0.24% |
| Ghost Tree Capital, LLC | 243,287 | $632,546 | 0.21% |
| Sio Capital Management, LLC | 246,036 | $639,694 | 0.20% |
| Artal Group S.A. | 1,725,000 | $4,485 | 0.19% |